1187594-09-7 | 2-(3-(4-(7H-Pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-1-(ethylsulfonyl)azetidin-3-yl)acetonitrile

Packsize	Purity	Availability	Price	Discounted Price
1mg	99%	in stock	$15.00	$11.00
2mg	99%	in stock	$22.00	$16.00
5mg	99%	in stock	$30.00	$21.00
10mg	98%	in stock	$42.00	$30.00
25mg	≥95%	in stock	$48.00	$34.00
50mg	≥95%	in stock	$76.00	$54.00
250mg	98%	in stock	$98.00	$69.00
1g	99%	in stock	$188.00	$132.00
5g	98%	in stock	$713.00	$499.00
10g	98%	in stock	$1,055.00	$739.00
25g	98%	in stock	$2,004.00	$1,403.00

Description

• Catalog Number: AB52938
• Chemical Name: 2-(3-(4-(7H-Pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-1-(ethylsulfonyl)azetidin-3-yl)acetonitrile
• CAS Number: 1187594-09-7
• Molecular Formula: C16H17N7O2S
• Molecular Weight: 371.4169
• MDL Number: MFCD21608464
• SMILES: N#CCC1(CN(C1)S(=O)(=O)CC)n1ncc(c1)c1ncnc2c1cc[nH]2

Computed Properties

• Complexity: 678
• Covalently-Bonded Unit Count: 1
• Heavy Atom Count: 26
• Hydrogen Bond Acceptor Count: 7
• Hydrogen Bond Donor Count: 1
• Rotatable Bond Count: 5
• XLogP3: -0.5

Literature

• Baricitinib in Patients with Refractory Rheumatoid Arthritis.

  The New England journal of medicine 20160331

• Reversal of Alopecia Areata Following Treatment With the JAK1/2 Inhibitor Baricitinib.

  EBioMedicine 20150401

• Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition.

  Nature medicine 20140901

• Discovery and development of Janus kinase (JAK) inhibitors for inflammatory diseases.

  Journal of medicinal chemistry 20140626

• Inhibition of Janus kinase/signal transducer and activator of transcription (JAK/STAT) signalling pathway in rheumatoid synovial fibroblasts using small molecule compounds.

  Clinical and experimental immunology 20131201

• Selective inhibition of JAK1 and JAK2 is efficacious in rodent models of arthritis: preclinical characterization of INCB028050.

  Journal of immunology (Baltimore, Md. : 1950) 20100501